Lundbeck genopslog dette
In neuroscience, sustainable success is not just about the next breakthrough – it is about consistent innovation over decades. I recently sat down with PharmaBoardroom to share insights on Lundbeck's evolution into a focused, sustainable innovator in neuroscience. Our journey combines over a century of heritage with a sharp vision for the future. 💡Key highlights from our conversation: ✔ Sustainable Growth Strategy: We're building long-term value through a balanced approach to innovation. Our aim? A new product launch every 3-4 years, supported by both internal R&D excellence and strategic external partnerships. ✔ Pipeline Sustainability: By 2026, we expect to have up to four assets in Phase III - a significant milestone in creating a mature, value-generating pipeline that will drive our future growth. ✔ Strategic Innovation Model: Nearly half our pipeline now comes from external sources, complementing our internal capabilities and creating a sustainable framework for continuous innovation. I am particularly proud of how we have demonstrated consistent delivery and tangible progress, with results regularly exceeding analyst forecasts. This performance is not coincidental - it reflects our systematic strategy and disciplined pursuit of sustainable growth opportunities. The future of neuroscience is bright, and Lundbeck is well-positioned to lead in this exciting era of innovation. Read the full interview here 👉 https://lnkd.in/dQRzg2ep #Lundbeck #Neuroscience #Innovation #SustainableGrowth #PharmaBoardroom
Why Lundbeck's CEO thinks we are entering the "decade of the brain" Charl van Zyl took over Lundbeck 18 months ago and immediately made their largest acquisition ever. His thesis? Neuroscience is having its moment again, and the smart money is moving fast. "What was once a high-risk arena with limited predictability is now becoming increasingly structured, with clear targets and genetically validated mechanisms," van Zyl explained during an exclusive conversation with Joseph Kun. The results speak for themselves. Lundbeck's revenue is growing at 16%, with their strategic products expanding at 24%. They've gone from scattered efforts to laser focus on three domains: neuropsychiatry, specialty neurology, and rare neurological diseases. Fascinatingly, they are also partnering with NVIDIA on AI-powered drug discovery. Van Zyl believes physicians will soon rely on digital tools for "second opinions" drawn from millions of datapoints. The stigma around mental health is breaking down, and the science is finally catching up. Learn more at https://lnkd.in/dnUNsNzm